Arginine deficiency undermines immune surveillance

Researchers found arginine was the most depleted amino acid across multiple disease contexts and showed in cell and mouse experiments that low arginine causes ribosomes to stall when making MHC‑I proteins, reducing immune visibility; modest arginine supplementation restored MHC‑I and improved outcomes in mice with cancer and viral infections. These are mechanistic and experimental results, not yet human clinical proof, but they point to a plausible, low‑cost lever affecting immunity. — If validated in humans, arginine status could become a public‑health and clinical focus (from dietary guidance to trials in oncology and infectious disease) and spark debates about supplement regulation and evidence standards.